Rituximab – USA

Rituximab – USA

Decision on IPR: Oct 31, 2018

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Final Written Decision
IPR2017-01168
04/28/2017
11/06/2017
Pfizer, Inc.
8,821,873
Biogen Inc.
 Claims 1–5 are unpatentable
US 8,821,873 (Biogen Inc; Exp: Jul 28, 2020)

1. A method of treating a patient with diffuse large cell lymphoma comprising administering anti-CD20 antibody and chemotherapy to the patient, wherein the patient is >60 years old, wherein the chemotherapy comprises CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone), and wherein the anti-CD20 antibody is administered to the patient in combination with stem cell transplantation regimen.
5. A method of treating a patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) to the patient, in combination with stem cell transplantation, wherein the patient is >60 years old.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved